PURA - Puration Reports $1.2 Million In Revenue With $500,000 Net Profit In 2018 Year-End Financial Report
April 16 2019 - 9:00AM
InvestorsHub NewsWire
PURA - Puration Reports $1.2
Million In Revenue With $500,000 Net Profit In 2018 Year-End
Financial Report
Dallas, TX -- April 16, 2019 -- InvestorsHub
NewsWire -- Puration, Inc. (USOTC:
PURA) (“PURA”) today announced filing the company’s annual
financial statement reporting over $1.2 million in revenue for
year-end December 31, 2018 with over $500,000 in net profit.
Management attributes the more than 350% revenue growth in 2018
from the less than $300,000 in revenue reported in 2017 to the
success of the company’s EVERx CBD Sports Beverage. With the company’s recently
reported enhanced partnership with Kali-Extracts, (USOTC:
KALY) (“KALY”), management expects cannabis beverage
diversification and continued rapid growth in 2019. PURA is
working closely with the company’s co-packer/partner Alkame
Holdings, (USOTC:
ALKM) to expand production capacity and keep up with PURA’s
growing sales. PURA is also working with North American
Cannabis Holdings, (aka USMJ) (USOTC:
USMJ) to update PURA’s distribution channels to keep up with
USMJ’s online retail sales at USMJ.com and simultaneously meet wholesale
demand. On Friday, this week, April 19th, 2019, PURA
management will publish an online shareholder report with more
details and insight on the company’s 2018 growth and ongoing
anticipated growth in 2019. The online report is expected to
include updates on PURA’s work with KALY to produce new beverages
and work with ALKM to increase production capacity and produce new
beverages.
For more information on Puration,
visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Oct 2023 to Oct 2024